As the cornerstone of cancer treatment, tyrosine kinase inhibitors (TKIs) have without a doubt opened an era of systemic treatment of HCC, and their combined treatment with anti PD1/PD-L1 agents has attracted much attention. Here, PDCD1 is linked to hepatocellular carcinoma.